Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma-Reference-Cited by-同舟云学术

Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma

Published:2014-04-02 Issue:13 Volume:44 Page:1329-1338
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Jo Masayasu¹²,Yasui Kohichiroh¹,Kirishima Toshihiko³,Shima Toshihide⁴,Niimi Toshihisa⁵,Katayama Takayuki¹⁵,Mori Takahiro⁶,Funaki Jun⁷,Sumida Yoshio¹⁸,Fujii Hideki⁹,Takami Shiro¹⁰,Kimura Hiroyuki¹¹,Mitsumoto Yasuhide⁶¹²,Minami Masahito¹,Yamaguchi Kanji¹,Yoshinami Naomi³,Mizuno Masayuki⁴,Sendo Rei⁴⁵,Tanaka Saiyu⁸,Shintani Hiroyuki³,Kagawa Keizo⁵,Okanoue Takeshi⁴,Itoh Yoshito¹

Affiliation:

1. Department of Molecular Gastroenterology and Hepatology; Graduate School of Medical Science; Kyoto Prefectural University of Medicine; Kyoto Japan

2. Department of Molecular Gastroenterology and Hepatology; North Medical Center Kyoto Prefectural University of Medicine; Yosano Japan

3. Department of Gastroenterology; Kyoto City Hospital; Kyoto Japan

4. Department of Internal Medicine; Aiseikai Yamashina Hospital; Kyoto Japan

5. Department of Gastroenterology; Otsu Municipal Hospital; Japan

6. Department of Gastroenterology; Japanese Red Cross Kyoto Daiichi Hospital; Kyoto Japan

7. Department of Gastroenterology and Hepatology; Saiseikai Suita Hospital; Suita Japan

8. Department of Gastroenterology; Social Insurance Kyoto Hospital; Kyoto Japan

9. Department of Gastroenterology; Fukuchiyama City Hospital; Fukuchiyama Japan

10. Department of Gastroenterology; Osaka General Hospital of West Japan Railway Company; Osaka Japan

11. Department of Gastroenterology; Koseikai Takeda Hospital; Kyoto Japan

12. Center for Digestive and Liver Diseases; Nara City Hospital; Nara Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hepr.12308/fullpdf

Reference15 articles.

1. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis;El-Serag;Gastroenterology,2007

2. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan;Ikai;Hepatol Res,2007

3. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: an update;Gauthier;Hepatol Res,2013

4. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

5. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial;Cheng;Lancet Oncol,2009

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world clinical effectiveness of sorafenib among patients with unresectable hepatocellular carcinoma at two centers in the United States;World Journal of Gastrointestinal Oncology;2023-10-15

2. Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma;Frontiers in Oncology;2022-08-02

3. Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?;Hepatology;2022-01-18

4. Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial;Liver Cancer;2022

5. Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma;Drugs & Aging;2021-06-21